Thursday, April 21, 2011

 The treatment of patients with mild to moderate Alzheimer's
(tyrosine kinase inhibitor) 
Please Help Support Alzheimer's Research Today! 
Your Alzheimer's donation will help billions live without it.

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer's disease. Entitled, ˜Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial', this article is freely accessible online from BioMed Central's peer-reviewed journal Alzheimer's Research and Therapy. This randomized placebo-controlled phase 2 trial, conducted by Professor François Piette (Hôpital Charles-Foix in Ivry-sur-Seine) and colleagues from 12 study centers across France, investigated the hypothesis that masitinib's targeted inhibitory action on mast cells may reduce the symptoms of Alzheimer's disease. A total of 35 patients were included in this study. Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's permeability. Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and activity of mast cells. A prospective, multicentre, randomized, controlled, double-blind, parallel-group, phase 3 study to compare the efficacy and safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with mild to moderate Alzheimer's disease over a 24 week duration. A total of 300 patients will be enrolled with masitinib being administered orally as an add-on therapy to standard care.  Read more: drugs.com

New analysis slams calcium supplements over heart problems
Researchers have warned that the indiscriminate use of calcium supplements ‘should be abandoned’, as a meta-analysis of 29,000 people suggests the risks of heart problems outweigh the potential benefits. Read morenutraingredients.com

No comments:

Post a Comment